|

Can Ketamine Therapy Be the Solution for Treatment Resistant Depression & Opioid Addiction?

Ketamine therapy is shaping up to be one of the best legally available treatments to relieve a wide range of mental health issues such as PTSD, addiction, depression and suicidal thoughts.

Ketamine’s origin story begins in the 1960s, where it was first synthesized as an anaesthetic for animals. A decade later, the FDA approved the drug as a method of anesthesia for people. Ever since, it has been used for a multitude of different purposes. Ketamine has proven its usefulness during the Vietnam War, where it was used to treat wounded soldiers. Skipping forward by another decade, the drug finds its popularity in clubs, but under another name: Special K.

Today, ketamine has a newfound purpose in clinics all around North America: treating patients suffering from a variety of mental illnesses ranging from depression, to anxiety, to obsessive disorder, addiction and PTSD. Yet, this multi-purpose drug is not yet approved as a treatment for any of the aforementioned diseases of the mind. However, it’s more expensive cousin, esketamine, has in fact obtained this approval.

In early 2019, Spravato, Janssen Pharmaceuticals’ ketamine-derivative “esketamine”, was approved by the U.S Food and Drug Administration ( FDA) to treat treatment-resistant depression (TRD), becoming the first alternative treatment for depression that is not an antidepressant. Later the same year, Spravato achieved a second approval, which allowed it to be prescribed to patients suffering from acute suicidal ideation.

In 2021, a systematic review of 83 published research papers, led by the University of Exeter and funded by the United Kingdom’s Medical Research Council, found ketamine therapy rapidly reduced symptoms of depression one to four hours after a single treatment, and the effect lasted up to two weeks.

Additionally, suicidal thoughts in patients reduced moderately to largely as early as four hours after treatment, and lasted on average between three and seven days.

Dr. Zinia Thomas at Radiance Wellness, St. Louis MO is a psychiatrist whose interest in utilizing the power of psychedelics to promote mental wellness and recovery in her patients with treatment-resistant depression and substance use disorder was peaked long before she began to utilize IV Ketamine as a therapeutic in her own clinic.

In this segment of Spotlight in Focus, Dr. Thomas shares her holistic approach and examples of what’s gotten amazing results for her patients.

Similar Posts

  • Does Jon Stewart Microdose Magic Mushrooms? | Plus Pirate Eye

    Does Jon Stewart Microdosing Magic Mushrooms?

    Have you ever wanted to try microdosing magic mushrooms before, because Jon Stewart wants to! On a recent podcast episode of The Problem with Jon Stewart, the political comedian opened his show by saying “I’ve been microdosing the whole week!”, before clarifying that he just WANTS to try psychedelic microdosing.

    The satirist, sometimes known as America’s Conscience, is one of the most influential voices in media over the last 3 decades. His short and funny forrow into the psychedelics debate should help further propel the issue into the mainstream.

    Can microdosing help depression? Can Microdosing help mental health? Jon Stewart thinks so, though this claim needs to be verified by the medical establishment.

    Microdosing has become a popular trend for professionals in the last few decades, so it is not surprising that Jon Stewart knows about it. He is a man with his finger on America’s pulse.

    Link to podcast: https://open.spotify.com/episode/3OZV5DLbn33bNSUluLS7oX?si=qVoGF4cCS76x_MrM9h_slw

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy
    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com
    Video editing: @themyaholy

    #jonstweart #thejonsteartproblem #psychedelics

  • MindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)

    Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news!

    Timestamps:

    0:00 – Intro
    1:00 – MindMed Begins a Mescaline Study
    4:35 – MindMed & The Chopra Foundation
    8:30 – Cybin Progresses Phase 2a psilocybin study
    11:56 – Mydecine announces Q1 Financials
    14:16 – Havn Life Sciences enters the Cluster Headaches Game
    16:30 – Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression

    Enjoy!
    Links:
    MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study:
    https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/

    MindMed Partners Up with The Chopra foundation:
    https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/

    Cybin (CYBN) Progresses Phase IIa psilocybin film strip study:
    https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/

    Mydecine (MYCO / MYCOF) Q1 Financials:
    https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update

    Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches
    https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/

    Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression
    https://psychedelicspotlight.com/wake-psilocybin-microdose-study/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifa…

    https://benzinga.grsm.io/thepsychedel…

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #HAVN

  • Welcome to Plant Medicine Week, by Microdose. Join the Psychedelic Revolution

    Buy tickets for Plant Medicine Week in Malta, April 5th-8th by using our promo link: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

    Get 50% off tickets via the link above or by inputting code PSYC at the checkout over at plantmedicineweek.com/tickets!

    Do you both love learning about psychedelics, and need a vacation in beautiful Malta? Well you are in luck, because Microdose.buzz is hosting a one of a kind event next month.

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    At the event you will be able to learn about the medical benefits, research, and business of psychedelics, as well as marijuana. The all-star studded line-up includes representatives from companies such as atai Life Sciences (ATAI), Awakn Life Sciences (AWKN, AWKNF) and more.

    From panels on psychedelics and sex, to how to make money investing in psychedelics, this event will have it all. Plus…AFTER PARTIES!

    No matter if you want to learn about LSD, MDMA, psilocybin, ketamine or more, this event will have it all. We already know that psychedelics can help with mental health, now hear it first hand from the scientists themselves.

    #Psychedelics #MentalHealth #Microdose

  • MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF) 🚀

    In this video, I discuss how MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF. 🔥

    MindMed has had a impressive run up in 2020. The MMED stock is up nearly 1,130% and what we all wonder is : Could MindMed Stock keep on rising? With a larger psychedelic pipeline than Compass Pathways (CMPS), MindMed has made huge advancements in 2020, one of which is its LSD Neutralizer Technology To Shorten and Stop LSD Trips, which is groundbreaking news for all players in the psychedelic medicines industry.

    MindMed has a handful of exciting programs in the works, some of which have important milestones coming up this year. Project Lucy is one of these programs, using therapeutic doses of LSD to treat anxiety disorders. If this gets the go-ahead from regulators, it will proceed with a clinical trial investigating LSD for anxiety disorders. If that happens, the mindmed stock could get a big boost. Another boost could be MindMed’s potential uplisiting on to the Nasdaq.

    Currently, the MindMed Stock trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ.

    Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMedStock #MindMed #MMED #MMEDF

  • My Neuroplastic Adventure with Victor Mifsud

    In this episode, Dennis Walker speaks with Victor Mifsud about how a few MDMA experiences helped him have a temporary remission of his retinitis pigmentosa, a disease which has caused him to be legally blind.